Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Cardinal Health
CAH
$55.3B
| $81.4M | 0.06% |
1,608,880
-385,840
| -19% | -$19.9M |
|
352
COPT Defense Properties
CDP
$4.15B
| $81.2M | 0.06% |
2,762,988
+59,982
| +2% | +$1.75M |
|
353
Simon Property Group
SPG
$71B
| $80.7M | 0.06% |
541,705
-249,900
| -32% | -$37.5M |
|
354
Keysight
KEYS
$60.9B
| $80.1M | 0.06% |
780,428
+51,600
| +7% | +$5.28M |
|
355
D.R. Horton
DHI
$41.2B
| $80.1M | 0.06% |
1,517,838
+161,700
| +12% | +$8.63M |
|
356
DHT Holdings
DHT
$2.96B
| $80.1M | 0.06% |
9,668,071
+2,089,576
| +28% | +$15.5M |
|
357
Evertec
EVTC
$1.75B
| $79.8M | 0.06% |
2,345,326
-90,175
| -4% | -$2.86M |
|
358
VICI Properties
VICI
$28.6B
| $79.8M | 0.06% |
3,122,200
+1,595,700
| +105% | +$38.6M |
|
359
Universal Display
OLED
$4.29B
| $79.5M | 0.06% |
385,739
+212,138
| +122% | +$40.1M |
|
360
Neurocrine Biosciences
NBIX
$16.2B
| $79.5M | 0.06% |
739,172
+735,272
| +18,853% | +$77M |
|
361
KB Home
KBH
$3.48B
| $79.4M | 0.06% |
2,315,990
-4,400
| -0.2% | -$152K |
|
362
Orion
OEC
$373M
| $79.1M | 0.06% |
4,097,796
-99,400
| -2% | -$1.8M |
|
363
Weyerhaeuser
WY
$17.8B
| $78.2M | 0.06% |
2,588,340
-92,400
| -3% | -$2.68M |
|
364
Annaly Capital Management
NLY
$17.6B
| $78.1M | 0.06% |
2,071,850
+1,137,050
| +122% | +$41.4M |
|
365
Occidental Petroleum
OXY
$58.7B
| $77.6M | 0.06% |
1,883,384
+914,500
| +94% | +$36.6M |
|
366
Verizon
VZ
$195B
| $77M | 0.06% |
1,254,393
-1,590,100
| -56% | -$95.9M |
|
367
MKS Inc
MKSI
$21.1B
| $76.5M | 0.06% |
695,283
-438,586
| -39% | -$45.9M |
|
|
ENDP
368
DELISTED
Endo International plc
ENDP
| $76.4M | 0.06% |
16,283,700
+2,293,700
| +16% | +$10.2M |
|
369
Progress Software
PRGS
$1.75B
| $76.1M | 0.06% |
1,832,517
+277,406
| +18% | +$11.3M |
|
|
HTO
370
H2O America
HTO
$2.61B
| $76M | 0.06% |
1,068,900
+10,500
| +1% | +$742K |
|
371
Royal Bank of Canada
RY
$295B
| $75.7M | 0.06% |
956,294
-1,351,683
| -59% | -$109M |
|
|
NVMI
372
Nova
NVMI
$13.1B
| $75.5M | 0.06% |
1,997,098
-63,602
| -3% | -$2.23M |
|
373
Alamos Gold
AGI
$14.3B
| $75.2M | 0.06% |
12,484,793
+954,862
| +8% | +$5.22M |
|
374
RELX
RELX
$60.1B
| $75.1M | 0.06% |
2,970,400
+175,328
| +6% | +$4.19M |
|
375
Jabil
JBL
$38.4B
| $74.9M | 0.06% |
1,811,576
+825,676
| +84% | +$31.7M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.